Risk of not receiving 2nd line therapy is high in EGFR mt+ pts: Real world data of certified lung cancer centers on treatment sequence in EGFR mt+ pts.

Julia Roeper,Markus Tiemann,Claas Wesseler,Gunther Wiest,Sandra Sackmann,Dieter Ukena,Markus Falk,Lukas Heukamp,Frank Griesinger

doi:10.1200/jco.2018.36.15_suppl.e21220

Risk of not receiving 2nd line therapy is high in EGFR mt+ pts: Real world data of certified lung cancer centers on treatment sequence in EGFR mt+ pts.

Julia Roeper, Markus Tiemann + Show 7 more

https://doi.org/10.1200/jco.2018.36.15_suppl.e21220

Copy DOI

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2018
Citations: 7

Affiliation: Pius Hospital Oldenburg, Pathologie Hamburg-West, Asklepios Klinikum Harburg, Klinikum Bremen-Mitte

#Number Of Pts #Significant PFS Benefit + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

e21220Background: Recently FLAURA study demonstrated significant PFS and numeric OS benefit for Osimertinib 1st line vs. 1st gen. TKI’s. The number of pts switching from 1st gen. to 3rd gen. TKI (3...

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.